Publications

BibTex format

@article{Paterson:2013:10.1136/gutjnl-2012-302039,
author = {Paterson, AL and Shannon, NB and Lao-Sirieix, P and Ong, C-AJ and Peters, CJ and O'Donovan, M and Fitzgerald, RC},
doi = {10.1136/gutjnl-2012-302039},
journal = {Gut},
pages = {1415--1424},
title = {A systematic approach to therapeutic target selection in oesophago-gastric cancer},
url = {http://dx.doi.org/10.1136/gutjnl-2012-302039},
volume = {62},
year = {2013}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PDFUpper GI cancerOriginal articleA systematic approach to therapeutic target selection in oesophago-gastric cancerFree    Anna L Paterson1, Nicholas B Shannon1, Pierre Lao-Sirieix1, Chin-Ann J Ong1, Christopher J Peters1, Maria O'Donovan1,2, Rebecca C Fitzgerald1Author affiliationsAbstractObjective The success of personalised therapy depends on identification and inhibition of the oncogene(s) on which that tumour is dependent. We aimed to determine whether a receptor tyrosine kinase (RTK) array could be used to select the most effective therapeutic strategies in molecularly heterogeneous oesophago-gastric adenocarcinomas.Design Gene expression profiling from oesophago-gastric tumours (n=75) and preinvasive stages (n=57) identified the active signalling pathways, which was confirmed using immunohistochemistry (n=434). RTK arrays on a cell line panel (n=14) determined therapeutic targets for in vitro cytotoxic testing. Feasibility of this personalised approach was tested in tumour samples (n=46).Results MAPK was the most frequently activated pathway (32/75 samples (42.7%)) with progressive enrichment in preinvasive disease stages (p<0.05) and ERK phosphorylation in 148/434 (34.3%) independent samples. Cell lines displayed a range of RTK activation profiles. When no RTKs were activated, tyrosine kinase inhibitors (TKIs) and a Mek inhibitor were not useful (MKN1). In lines with a dominant phosphorylated RTK (OE19, MKN45 and KATOIII), selection of this TKI or Mek in nM concentrations induced cytotoxicity and inhibited Erk and Akt phosphorylation. In cells lines with complex activation profiles (HSC39 and OE33), a combination of TKIs or Mek inhibition (in nM concentrations) was necessary for cytotoxicity and inhibition of Erk and Akt phosphorylation. Human tumours demonstrated diverse activation profiles and 65% of cases had two or more active RTKs.Conclusions The MAPK pathway is commonly activated in oesophago-gastric cancer following activation of a variety of RTKs.
AU  - Paterson,AL
AU  - Shannon,NB
AU  - Lao-Sirieix,P
AU  - Ong,C-AJ
AU  - Peters,CJ
AU  - O'Donovan,M
AU  - Fitzgerald,RC
DO  - 10.1136/gutjnl-2012-302039
EP  - 1424
PY  - 2013///
SN  - 0017-5749
SP  - 1415
TI  - A systematic approach to therapeutic target selection in oesophago-gastric cancer
T2  - Gut
UR  - http://dx.doi.org/10.1136/gutjnl-2012-302039
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324422400007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/61318
VL  - 62
ER  -

Download

MrChristopherPeters

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)